Posted 17 July 2012
By Hoss A. Dowlat, PhD
This two-part series provides insights into the new paradigm of biosimilar medicines based on approval and medical experience postapproval. It proposes a framework for the understanding, development and acceptance of a new generation of biologic medicines, biosimilars, in the US and worldwide.
Share this article:
Categories: Features, FDA, EMA
Tags: MAbs, Biogenerics, proteins, biosimilar, safety, Follow-on Biologics, Biologics, clinical trials, risk